CJC-1295 / Ipamorelin (No DAC) Research Guide: Identity, Literature, Analysis and Documentation
Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.
This blend pairs two peptides that act through different receptors in the growth hormone axis: a 29-residue analogue of growth-hormone-releasing hormone, and the pentapeptide secretagogue ipamorelin. The name needs care before anything else. In the published literature, CJC-1295 usually means a molecule that carries an albumin-binding group called the drug affinity complex (DAC). The peptide in this vial does not carry it, and is more precisely called modified GRF(1-29). This page sets out the identity of both components, what the literature on each covers, what a two-component certificate should show, and the reports on file for StarBio’s lot.
Identity
| Name | CJC-1295 without DAC (modified GRF 1-29) and ipamorelin |
|---|---|
| Type | Two-peptide research blend: a GHRH(1-29) analogue and a growth hormone secretagogue |
| Component 1 | Modified GRF(1-29): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2, 3367.9 g/mol |
| Component 2 | Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2, 711.85 g/mol, CAS 170851-70-4 |
| Labelled total | 10 mg (5 mg of each) |
Origin and history
CJC-1295 was developed by ConjuChem in Montreal in the mid-2000s. Its peptide part is GHRH(1-29) amide with four substitutions chosen to remove the parent sequence’s weak points: D-alanine at position 2 against enzymatic cleavage, glutamine in place of the deamidation-prone asparagine at 8, alanine in place of glycine at 15, and leucine in place of the oxidation-prone methionine at 27. The original molecule added a reactive lysine derivative, the DAC, that binds serum albumin. The same tetrasubstituted peptide without that group is what is sold as CJC-1295 without DAC. Ipamorelin was described by a Novo Nordisk group in 1998 as the first growth hormone secretagogue selective for its receptor. It is built from unnatural residues, including aminoisobutyric acid and D-2-naphthylalanine.
What the literature covers
The references on file for this compound span several research areas. They are listed here as areas of study, not as results.
- CJC-1295, the DAC-bearing form. A 2006 pharmacokinetic study in healthy adults [1] and a study in the GHRH knockout mouse the same year [11]. Both concern the molecule with the drug affinity complex, not the DAC-free peptide in this blend.
- Ipamorelin. The original characterisation (1998) [2], rat studies of bone formation and nitrogen balance [6, 8], somatotroph response in vitro [10], a 2024 ferret model [4] and ghrelin-receptor imaging ligands (2018) [12].
- Analytical and anti-doping chemistry. Detection methods for GHRH analogues (2021) [3], an immuno-PCR screen in equine plasma (2019) [5] and the identification of CJC-1295 in an unknown preparation (2010) [9].
- Unregulated use. A 2016 study of online discussion of CJC-1295 [7], which documents that the name circulates well outside laboratories. StarBio supplies this material for laboratory research only.
There is no published literature on the two peptides as a blend.
Analytical notes
The two components are easy to separate: 711.85 Da against 3367.9 Da, with very different retention. The catch is detection. Ipamorelin contains a naphthyl group, which absorbs ultraviolet light far more strongly than ordinary residues, so the two peaks have different response factors and their area ratio is not a mass ratio. A purity figure tells you the vial holds little besides the two peptides. It cannot tell you that they are present 5 mg to 5 mg.
That is why a blend needs per-component quantification, and StarBio’s Janoshik report gives it: 4.97 mg of the GHRH analogue and 4.43 mg of ipamorelin against a label of 5 mg each. The modified GRF sequence has no methionine and no asparagine, so the oxidation and deamidation sites of the parent hormone are absent. With three arginines and two lysines it is basic and adsorbs to untreated glass and plastic. A mass of 3647 Da on a certificate would indicate the DAC-bearing molecule, which is a different product.
Storage and stability
- Lyophilized powder
- Store at -20 °C
- Protect from light
- Avoid repeated freeze-thaw cycles
- In solution: 2-8 °C, short term
Documentation for StarBio lots
Every StarBio lot is analysed by an independent laboratory. The table lists the reports on file for this compound.
| Variant | Laboratory / report | HPLC purity | Labelled / measured | Tested | |
|---|---|---|---|---|---|
| CJC-1295 no-DAC 5 mg + Ipamorelin 5 mg | Janoshik Analytical #136386 | identity / content | 10 mg total / CJC 4.97 mg / Ipa 4.43 mg | Apr 22, 2026 | report |
| CJC-1295 / Ipamorelin 10 mg | Medutest WWB-CP10-8748 | 99.27% | 10 mg | Feb 25, 2026 | report |
Current certificates are in the COA Library; the verify-lot form connects an order to its batch record.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006, PMID 16352683.
- Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 1998, PMID 9849822.
- Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug testing and analysis, 2021, PMID 34665524.
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024, PMID 39043357.
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug testing and analysis, 2019, PMID 30489688.
- Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009, PMID 19231263.
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016, PMID 26771670.
- The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001, PMID 11735244.
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010, PMID 21204297.
- Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002, PMID 12168778.
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006, PMID 16822960.
- Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. European journal of medicinal chemistry, 2018, PMID 30282322.
Product page: CJC-1295 / Ipamorelin (No DAC). Related guides: Ipamorelin research guide, Sermorelin research guide, what 99% purity means, storing lyophilized peptides.
For laboratory research use only. Not for human or veterinary use.
Compared with related compounds: Sermorelin vs CJC-1295 vs Tesamorelin.
Questions about CJC-1295 / Ipamorelin (No DAC)
What is CJC-1295 / Ipamorelin (No DAC)?
CJC-1295 / Ipamorelin (No DAC) is a blend: GHRH analog + growth hormone secretagogue (CJC-1295 no-DAC + Ipamorelin). It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.
Is CJC-1295 / Ipamorelin (No DAC) the same as Modified GRF(1-29) and ipamorelin and Mod GRF 1-29 / ipamorelin blend?
CJC-1295 / Ipamorelin (No DAC) is also listed as Modified GRF(1-29) and ipamorelin and Mod GRF 1-29 / ipamorelin blend. On a certificate or vial label, the sequence identify the material regardless of which name is used.
Is StarBio's CJC-1295 / Ipamorelin (No DAC) independently tested?
Yes. The current CJC-1295 / Ipamorelin (No DAC) batch was tested by Janoshik Analytical (Janoshik Analytical report #136386), measured content CJC 4.97 mg / Ipa 4.43 mg against 10 mg total labelled, tested Apr 22, 2026. The report is on file in the COA library (report page). Janoshik Analytical reports can be checked on janoshik.com with the report number.
How should CJC-1295 / Ipamorelin (No DAC) be stored?
Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.
Where can I buy CJC-1295 / Ipamorelin (No DAC) for laboratory research?
StarBio sells CJC-1295 / Ipamorelin (No DAC) as 10 mg at $59.99, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.
New reports and guides, by email
A short note when a new laboratory report is published, when a compound returns to stock, and when a new guide goes up. Nothing else. Leave whenever you like.
For laboratory research use only. No dosing or protocol content is ever sent.

